Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have received a consensus recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $93.50.

A number of analysts recently weighed in on the stock. Piper Sandler increased their price objective on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, January 13th. Wells Fargo & Company increased their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. Canaccord Genuity Group increased their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. HC Wainwright reaffirmed a “buy” rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 8,273 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total value of $413,650.00. Following the completion of the sale, the chief executive officer now directly owns 2,195,712 shares in the company, valued at $109,785,600. This trade represents a 0.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Theodore Alan Huizenga sold 967 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $40,710.70. Following the completion of the sale, the chief accounting officer now owns 50,265 shares of the company’s stock, valued at approximately $2,116,156.50. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 142,858 shares of company stock valued at $6,093,035 over the last ninety days. 5.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its stake in Ultragenyx Pharmaceutical by 259.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 493 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $35,000. Human Investing LLC acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $42,000. True Wealth Design LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth $43,000. Finally, Van ECK Associates Corp lifted its stake in shares of Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 273 shares during the period. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Trading Down 2.1 %

Shares of NASDAQ:RARE opened at $40.02 on Friday. Ultragenyx Pharmaceutical has a 12 month low of $37.02 and a 12 month high of $60.37. The company has a 50-day moving average price of $42.75 and a 200 day moving average price of $48.89. The company has a market cap of $3.70 billion, a price-to-earnings ratio of -6.31 and a beta of 0.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. As a group, equities analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.